• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23353 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments]
2006     Center for Medical Technology Assessment (CMT) [Health economic evaluation of two methods for post-operative pain treatment after abdominal operation]
2021     Center for Drug Evaluation (CDE) [Health economic evaluation of three listed anti-cancer medications]
2009     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Health economic analysis of diagnostic strategies of colorectal cancer - a health technology assessment]
2000     Basque Office for Health Technology Assessment (OSTEBA) [Health centre major surgery in Osakidetza - Basque Health Service]
2008     Health Council of the Netherlands Gezondheidsraad (GR) [Health care for the elderly with multimorbidity]
2003     Basque Office for Health Technology Assessment (OSTEBA) [Health care for terminal patients: systematic review and analysis of health care in hospitals of the Basque Country]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Health care efficiency and cost-efficacy of rapid diagnostic testing of methicillin-resistant Staphylococcus aureus]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Health and health services use in immigrant and native population in Spain]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [HD Analyzer® in cataract and dry eye]
2011     Committee for New Health Technology Assessment (CNHTA) [HBV entecavir resistance mutation [PCR-RFMP]]
2010     Committee for New Health Technology Assessment (CNHTA) [HBV drug resistance mutation[multiplex-PCR]]
2010     Committee for New Health Technology Assessment (CNHTA) [HBB(beta-hemoglobin)gene deletion Test[MLPA]]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Haploidentical bone marrow transplantation in patients with blood cancers]
2015     National Evidence-based Healthcare Collaborating Agency (NECA) [Handbook for clinical practice guideline developer]
2010     Committee for New Health Technology Assessment (CNHTA) [Hand transplantation]
2020     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Halcyon intensity-modulated beam conformal image-guided volumetric radiotherapy system for oncology treatment]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Hair micro transplant using follicular unit extraction technique for alopecia]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Hadrontherapy in the treatment of cancer]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Hadron therapy: proton and carbon ion therapy - a review of clinical evidence of efficacy, ongoing research and reimbursement]
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Hadron therapy in children: evidence synthesis for 15 paediatric tumours. Report based on Belgian (KCE) HTA report]
2002     The Netherlands Organisation for Health Research and Development (ZonMw) [Gynecological cancer: diagnostic value of radiological tests]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guselkumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guselkumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guselkumab (plaque psoriasis) - Addendum to Commission A17-60]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides for the pharmacological treatment of STBBIs]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: wound care-assessment, management, and optimal treatment use]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: use of electrodiagnostic testing in the neurological investigation - electromyography and nerve conduction studies]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: urinary tract infection in people aged 14 and over - diagnostic guidelines, optimal use of 1st- and 2nd-line treatments and follow-up ]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: urethral discharge - diagnostic measures and pharmacological treatment]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: updated recommendations for adjusting antidiabetic medication in type 2 diabetes]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: updated recommendations for adjusting antidiabetic medication in type 2 diabetes]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: update of the tool for choosing the dosage of monoclonal antibodies targeting PD 1 or PD-L1]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: update of the optimal usage guide on sexually transmitted and blood borne infections – confirmed Mycoplasma genitalium infection]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: unusual vaginal discharge - diagnostic measures and pharmacological treatment]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: type 2 diabetes screening and cardiovascular risk assessment]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: the management of myalgic encephalomyelitis / chronic fatigue syndrome]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: Syphilis - detection, diagnosis, optimal antibiotic use, and follow-up]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: relevance of preoperative consultation and testing for low-risk elective surgery in people aged 16 and over]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: Quality indicators for the care and services provided in long-term left ventricular assist device implantation programs]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: optimal use of immunoglobulin in fertility, cardiology and other indications]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: optimal use of echocardiography in Québec- diagnosis and follow-up of chronic heart failure]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: optimal use of cardiac ultrasound in Québec - diagnosing patients with a murmur and monitoring patients with valve diseases (native and prosthetic valves)]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: methodological report in support of the reflection guide supporting clinical and organizational practices in rehabilitation services for young people with adjustment problems aged 10 or older]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: measurement and monitoring of total serum bilirubin in a newborn with signs suggestive of neonatal jaundice]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: major depressive disorder during pregnancy]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: judicious blood culture use]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: intravenous iron therapy in adults]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: intra-abdominal infections in adults]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiating pharmacological treatment for oropharyngeal mucositis in a patient receiving cancer therapy]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiating osteodensitometry following the assessment of fracture risk with the FRAX tool]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiating an HPV test and following up on results for cervical cancer screening]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiate diagnostic measures in the presence of symptoms and signs suggestive of urinary tract infection (cystitis and pyelonephritis) and initiate first-line pharmacological treatment for cystitis in an individual 14 years of age and older]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: hormone therapy for the management of the clinical manifestations of menopause]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: delirium in elderly persons in emergency departments - prevention, assessment and management]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: COVID-19 - optimal use of parmacological treatments]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: chronic obstructive pulmonary disease- detection, diagnosis, optimal use of medications and inhalation devices, and global management]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: asthma management in children and adults]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: Acute myeloid leukemia treatment algorithm]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: acute exacerbation of chronic obstructive pulmonary disease -diagnostic approach, optimal use of treatments, and follow-up]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards : systemic treatment algorithm for metastatic or advanced colorectal cancer, palliative intent]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guides and glossary for hospital quality reports - Rapid report]
2011     Andalusian Health Technology Assessment Area (AETSA) [Guidelines to produce citizen-friendly health technology assessment reports]
1995     Basque Office for Health Technology Assessment (OSTEBA) [Guidelines for chronic leg ulcers in primary health care]
2005     Basque Office for Health Technology Assessment (OSTEBA) [Guidelines for assessing the impact of projects, programmes or non-health policies on health and well-being of individuals]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: urinary catheter placement in an adult with functional autonomy decline presenting with symptoms suggestive of acute urinary retention]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: standards for the management of acute ST-segment elevation myocardial infarction (STEMI) in Québec (update of April 2021)]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: respiratory multiplex NAAT (8 or more targets)]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: post-tick bite antibiotic prophylaxis to prevent Lyme disease, report in support of the knowledge transfer tools, the Québec’s national medical protocol and the collective prescription template]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: oral opioid agonists for the treatment of opioid use disorder]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: optimal use of immunoglobulins in infectious diseases]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: optimal use of immunoglobulin in solid organ transplantation]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: needs analysis grid for families followed by Integrated Perinatal and Early Childhood Services (SIPPE)]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: managing the risk of suicide and self-harm among youths living in rehabilitation centres for young persons with adjustment problems]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: initiating pharmacotherapy for relapse prevention in a person with alcohol use disorder]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: initiating pharmacological treatment for clearing an occluded central venous access device (CVAD)]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: initiating diagnostic measures in a person with signs and symptoms suggestive of a urinary tract infection (cystitis or pyelonephritis) and initiating first-line pharmacological treatment for cystitis in an adult with functional autonomy decline]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: initiating blood work for the purpose of evaluating diagnosed or suspected alcohol use disorder]
2017     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: fibrinolysis in ST-segment elevation acute myocardial infarction]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: autonomy in intellectually disabled young people aged 6 to 21 years]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: alcohol withdrawal and relapse prevention]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: administration of benzodiazepines or gabapentin prescribed via an individual prescription for alcohol withdrawal]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: assessment and risk management of severe neurological complications following mild traumatic brain injury]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards, updated on May 4th 2020 : guide to preventing and treating chemotherapy or radiotherapy-induced nausea and vomiting in adults]
2018     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards, English version updated in June 2020: requirements relating to the institutions responsible for the operation of acute healthcare facilities designated within the Quebec trauma network]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis on depression]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for updating the DMP "Heart failure"]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for updating the DMP "Asthma"]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP “type 1 diabetes”]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP “Osteoporosis”]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP “Depression”]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP “Coronary heart disease”]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP “Chronic back pain”]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP "Rheumatoid Arthritis“]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP "Breast cancer"]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the DMP "type 2 diabetes"]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the DMP "osteoporosis" - rapid report]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the DMP "COPD"]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for obesity - children and adolescents]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for obesity - adults]